1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.
Saved in:
| Title: | 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing. |
|---|---|
| Authors: | Markman, B.1 (AUTHOR), Day, D.1 (AUTHOR), Park, J.J.W.2 (AUTHOR), Coward, J.3 (AUTHOR), Bishnoi, S.4 (AUTHOR), Kotasek, D.4 (AUTHOR), Eek, R.5 (AUTHOR), Brown, M.P.6 (AUTHOR), Lemech, C.7 (AUTHOR), Kuo, J.7 (AUTHOR), Prawira, A.8 (AUTHOR), Strother, R.9 (AUTHOR), Zhang, Q.10 (AUTHOR), Wang, L.11 (AUTHOR), Chen, R.11 (AUTHOR), Ma, Y.11 (AUTHOR), Qin, Z.11 (AUTHOR), Tse, A.10 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS722-S722. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.1177 |
